Multiple pathways control cell growth and transformation: Overlapping and independent activities of p53 and p21(Cip1/WAF1/Sdi1)

Journal of Pathology

Volumn 183, Issue 2, 1997, Pages 134-140

  Cox, Lynne S ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Apoptosis; Cancer; Cell cycle control; P21 Cip1 WAF1 Sdi1; p53; Prognostic markers

Indexed keywords

CYCLINE; MYOD PROTEIN; PHOSPHOTRANSFERASE; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR;

ANIMAL CELL; APOPTOSIS; CANCER GROWTH; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; DNA DAMAGE; HUMAN; HUMAN CELL; LARYNX CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; ENZYME INHIBITORS; GENES, P53; HUMANS; NEOPLASM PROTEINS; TRANSCRIPTION, GENETIC;

EID: 0030866223     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9896(199710)183:2<134::AID-PATH960>3.0.CO;2-D     Document Type: Review

References (66)

1. Kernohan NM, Cox LS. Regulation of apoptosis by Bcl-2 and its related proteins: immunochemical challenges and therapeutic implications. J Pathol 1996; 179: 1-3.
2. WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. J Pathol 1997; 183: 156-163.
3. Lane DP. p53, guardian of the genome. Nature 1992; 358: 15-16.
4. Harvey M, Sands AT, Weiss RS, et al. In vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 1993; 8: 2457-2467.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
6. Barnes DM, Dublin EA, Fisher CJ, Levison DA, Millis RR. Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? Hum Pathol 1993; 24: 469-476.
7. Barnes DM, Hanby AM, Gillett CE, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992; 340: 259-263.
8. MacGeoch C, Barnes DM, Newton JA, et al. p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 1993; 11: 239-250.
9. Lavieille JP, Lubin R, Soussi T, Reyt E, Brambilla C, Riva C. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. Anticancer Res 1996; 16: 2385-2388.
10. Lu X, Lane DP. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes? Cell 1993; 75: 765-778.
11. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997; 17: 355-363.
12. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. BioEssays 1995; 17: 501-508.
13. Hupp TR, Meek DW, Midgley CA, Lane DP. Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875-886.
14. Hupp TR, Meek DW, Midgley CA, Lane DP. Activation of the cryptic DNA binding function of mutant forms of p53. Nucleic Acids Res 1993; 21: 3167-3174.
15. Meek DW, Street AJ. Nuclear protein phosphorylation and growth control. Biochem J 1992; 287: 1-15.
16. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nature Genet 1992; 1: 45-49.
17. Kastan MB, Zhan Q, El-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telengiectasia. Cell 1992; 71: 587-597.
18. Miyashita T, Reed JC. Tumour suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80: 293-299.
19. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumour suppressor protein. EMBO J 1994; 13: 4816-4823.
20. Brain R, Jenkins JR. Human p53 directs DNA strand reassociation and is photolabelled by 8-azido ATP. Oncogene 1994; 9: 1775-1780.
21. Oberosler P, Hloch P, Ramsperger U, Stahl H. p53-catalyzed annealing of complementary single-stranded nucleic acids. EMBO J 1993; 12: 2389-2396.
22. Cox LS, Hupp T, Midgley CA, Lane DP. A direct effect of activated human p53 on eukaryotic DNA replication. EMBO J 1995; 14: 2099-2105.
23. Clore GM, Omichinski JG, Sakaguchi K, et al. High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. Science 1994; 265: 386-391.
24. Clore GM, Ernst J, Clubb R, et al. Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol 1995; 2: 321-333.
25. Friend S. p53: a glimpse at the puppet behind the shadow play. Science 1994; 265: 334-335.
26. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245.
27. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
28. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-704.
29. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF-1, a potential mediator of p53 tumour suppression. Cell 1993; 75: 817-825.
30. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996; 10: 2438-2451.
31. Cip1 in muscle and other terminally differentiating cells. Science 1995; 267: 1024-1027.
32. Li CY, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. J Biol Chem 1995; 270: 4971-4974.
33. Qiu X, Forman HJ, Schonthal AH, Cadenas E. Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinylbenzoquinones by HCT116 cells. J Biol Chem 1996; 271: 31915-31921.
34. James SY, Mackay AG, Colston KW. Effects of 1, 25-dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996; 58: 395-401.
35. Greenhalgh DA, Wang XJ, Donehower LA, Roop DR. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res 1996; 56: 4413-4423.
36. Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995; 267: 1018-1021.
37. WAF1/Cip1 is induced through a p300-dependent mechanism during NGF-mediated neuronal differentiation of PC12 cells. Oncogene 1996; 13: 2047-2054.
38. Zeng YX, El-Deiry WS. Regulation of p21WAF1/Cip1 expression by p53-independent pathways. Oncogene 1996; 12: 1557-1564.
39. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996; 74: 208-215.
40. DiGiuseppe JA, Redston MS, Yeo CJ, Kern SE, Hruban RH. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 47: 884-888.
41. Bar JK, Markowska J, Harlozinska A, Sedlaczek P, Nowak M, Roszak A. Relation between infection with human papilloma viruses and expression of p21 and p53 oncoproteins in patients with cancer of the uterine cervix. Eur J Gynaecol Oncol 1996; 17: 283-285.
42. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-1163.
43. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. Mol Biol Cell 1993; 4: 897-906.
44. Zhang H, Hannon GJ, Beach D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev 1994; 8: 1750-1758.
45. Sjalander A, Birgander R, Rannug A, Alexandrie AK, Tornling G, Beckman G. Association between the p21 codon 31 A1 (arg) allele and lung cancer. Hum Hered 1996; 46: 221-225.
46. Sun Y, Hildesheim A, Li H, et al. No point mutation but a codon 31ser→arg polymorphism of the WAF-1/CIP-1/p21 tumor suppressor gene in nasopharyngeal carcinoma (NPC): the polymorphism distinguishes Caucasians from Chinese. Cancer Epidemiol Biomarkers Prev 1995; 4: 261-267.
47. Bhatia K, Fan S, Spangler G, et al. A mutant p21 cyclin-dependent kinase inhibitor isolated from a Burkitt's lymphoma. Cancer Res 1995; 55: 1431-1435.
48. Shiohara M, el Deiry WS, Wada M, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-3784.
49. WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-684.
50. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995; 55: 5187-5190.
51. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996; 381: 713-716.
52. WAF1/CIP1 -/-human cancer cells. Cancer Res 1996; 56: 2250-2255.
53. Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994; 371: 534-537.
54. Shivji MKK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ. Cip1 inhibits DNA replication but not PCNA-dcpcndent nucleotide excision repair. Curr Biol 1994; 4: 1062-1068.
55. Cip1 compete for binding to the same site on PCNA: a possible mechanism for regulation of DNA replication. Oncogene 14: 2313-2321.
56. Yang ZY, Perkins ND, Ohno T, Nabel EG, Nabel GJ. The p21 cyclindependent kinase inhibitor suppresses tumorigenicity in vivo. Nat Med 1995; 1: 1052-1056.
57. Chen J, Willingham T, Shuford M, et al. Effects of ectopic overexpression of p21(WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumor cells. Oncogene 1996; 13: 1395-1403.
58. WAF1 and proliferating cell nuclear antigen. Curr Biol 1995; 5: 275-282.
59. WAF1. Curr Biol 1997; 7: 71-80.
60. Soddu S, Blandino G, Scardigli R, et al. Interference with p53 protein inhibits hematopoietic and muscle differentiation. J Cell Biol 1996; 134: 193-204.
61. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208.
62. Rowan S, Ludwig RL, Haupt Y, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996; 15: 827-838.
63. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16: 4952-4960.
64. Polyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996; 10: 1945-1952.
65. Gottlieb MT, Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996; 1287: 77-102.
66. Hickman JA, Potten CS, Merritt AJ, Fisher TC. Apoptosis and cancer chemotherapy. Philos Trans R Soc London Ser B 1995; 345: 83-89.